Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced the first patient has received its investigational new drug, PEGPH20 in combination with Merck’s KEYTRUDA (pembrolizumab) in a clinical …
Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced that Janssen Biotech, Inc.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced that the first healthy subject has been dosed in a Phase 1 clinical trial evaluating the safety, tolerability and …
Recently, various executives have taken part in insider buying activity for the stocks of Tesla Motors Inc (NASDAQ:TSLA), SolarCity Corp (NASDAQ:SCTY), Cytokinetics, Inc. (NASDAQ:CYTK), and Halozyme …
Halozyme Therapeutics, Inc. (NASDAQ:HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today named Michael J.
Halozyme Therapeutics, Inc. (NASDAQ:HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results for the second quarter endedJune 30, 2015.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced the Pancreas Center at the University of California, San Francisco (UCSF) has initiated a clinical research study of Halozyme’s …
Halozyme Therapeutics, Inc. (NASDAQ:HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the appointment of Jeffrey W.
In a research note issued today, MLV analyst Arlinda Lee reiterated a Buy rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO) with a price target of $20, following the …
MLV’s healthcare analyst Arlinda Lee weighed in today with his views on Halozyme Therapeutics, Inc. (NASDAQ:HALO), after the company announced interim findings from the ongoing phase …
